Company: HCWB
Filing Date: 2025-04-01
Form Type: 8-K
Source: 0000950170-25-048619
Chunk: 2

Company: HCW Biologics Inc.
Filing Date: 2025-04-01
Form: 8-K
Item: Item 3.03
Chunk 2
---
 become effective at or about 12:01 am Eastern time on April 11, 2025. A copy of the Certificate of Amendment of Certificate of Incorporation is attached as Exhibit 3.1a and the related Certificate of Correction is attached as Exhibit 3.1b to this Current Report.

Stockholder Approval. As disclosed above and as reported on Form 8-K filed on April 1, 2025, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to implement one or more reverse stock splits of the outstanding shares of the Common Stock (as necessary to maintain a listing of the Common Stock on Nasdaq in an aggregate range from one-for-twenty (1:20) up to one-for-fifty (1:50), or anywhere between, all as determined in the sole discretion of the Company’s Board of Directors. The stockholder approval occurred at the Special Meeting of Stockholders held on March 31, 2025 at 10 a. m. Eastern time.

Capitalization. Prior to the Reverse Stock Split, the Company was authorized to issue 250,000,000 shares of Common Stock. There will be no change in the number of authorized shares as a result of the Reverse Stock Split. As of March 25, 2025, there were 44,934,120 shares of Common Stock outstanding. As a result of the Reverse Stock Split, there will be approximately 1,123,353 shares

of Common Stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The number of shares of preferred stock that the Company is authorized to issue will not be impacted; none is currently issued and outstanding.

Immediately after the Reverse Stock Split, each stockholder’s relative ownership interest in the Company and proportional voting power will remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares of Common Stock into whole shares.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements related to the Reverse Stock Split, the effectiveness of the Certificate of Amendment of Certificate of Incorporation, as corrected, and the Company’s ability to regain and maintain compliance with Nasdaq’s minimum bid price requirement, as well as statements, other than historical facts, that address activities, events, or developments that the company intends, expects, projects, believes, or anticipates will or may occur in the future. These statements are often characterized by terminology such as